Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats

Treatment of advanced thyroid cancer with targeted therapies: ten years of experience

(2016) David Viola et al.   ENDOCRINE-RELATED CANCER

Effects of receptor tyrosine kinase inhibitors on VEGF165a- and VEGF165b-stimulated gene transcription in HEK-293 cells expressing human VEGFR2

(2015) Joanne J Carter et al.   BRITISH JOURNAL OF PHARMACOLOGY

Hypertension induced by chemotherapeutic and immunosuppresive agents: A new challenge

(2015) Simon Abi Aad et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With SunitinibNovelty and Significance

(2015) Stephanie Lankhorst et al.   HYPERTENSION

Cediranib Aims for a Comeback

(2015) C. Schmidt   JNCI-Journal of the National Cancer Institute

Cediranib Aims for a Comeback

(2015) C. Schmidt   JNCI-Journal of the National Cancer Institute

Treatment of Hypertension and Renal Injury Induced by the Angiogenesis Inhibitor Sunitinib

(2014) Stephanie Lankhorst et al.   HYPERTENSION

Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats

(2014) Takehito Isobe et al.   JOURNAL OF TOXICOLOGICAL SCIENCES

Cardiovascular responses to retigabine in conscious rats - under normotensive and hypertensive conditions

(2013) L V Fretwell et al.   BRITISH JOURNAL OF PHARMACOLOGY

Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension

(2012) Peter Kruzliak et al.   ANGIOGENESIS

Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors

(2012) Francesca Musumeci et al.   JOURNAL OF MEDICINAL CHEMISTRY

Drug-induced Hypertension: An Unappreciated Cause of Secondary Hypertension

(2011) Ehud Grossman et al.   AMERICAN JOURNAL OF MEDICINE

Sunitinib, a Receptor Tyrosine Kinase Inhibitor, Increases Blood Pressure in Rats without Associated Changes in Cardiac Structure and Function

(2011) E. Blasi et al.   Cardiovascular Therapeutics

The Vascular Endothelial Growth Factor Receptor Inhibitor Sunitinib Causes a Preeclampsia-Like Syndrome With Activation of the Endothelin System

(2011) Mariëtte H.W. Kappers et al.   HYPERTENSION

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats

(2010) SM Gardiner et al.   BRITISH JOURNAL OF PHARMACOLOGY

Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology

(2010) Thomas Eschenhagen et al.   EUROPEAN JOURNAL OF HEART FAILURE

Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors

(2010) Emily S. Robinson et al.   HYPERTENSION

Hypertension Induced by the Tyrosine Kinase Inhibitor Sunitinib Is Associated With Increased Circulating Endothelin-1 Levels

(2010) Mariëtte H.W. Kappers et al.   HYPERTENSION

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

(2010) Michael L. Maitland et al.   JNCI-Journal of the National Cancer Institute

Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer

(2010) Rebecca L Stone et al.   LANCET ONCOLOGY

Anti-Vascular Endothelial Growth Factor Therapies and Cardiovascular Toxicity: What Are the Important Clinical Markers to Target?

(2010) C. Vaklavas et al.   ONCOLOGIST

Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression

(2009) Carie S. Facemire et al.   HYPERTENSION

Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects

(2009) Mariëtte HW Kappers et al.   JOURNAL OF HYPERTENSION

Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors

(2009) Kelly L. Snider et al.   Targeted Oncology

Inhibition of Vascular Endothelial Growth Factor-A Signaling Induces Hypertension: Examining the Effect of Cediranib (Recentin; AZD2171) Treatment on Blood Pressure in Rat and the Use of Concomitant Antihypertensive Therapy

(2008) J. O. Curwen et al.   CLINICAL CANCER RESEARCH

High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor

(2007) Damien Pouessel et al.   EUROPEAN UROLOGY